Developing urinary pyrrole–amino acid adducts as non-invasive biomarkers for identifying pyrrolizidine alkaloids-induced liver injury in human

Lin Zhu1 · Chunyuan Zhang1 · Wei Zhang2 · Qingsu Xia3 · Jiang Ma1 · Xin He1 · Yisheng He1 · Peter P. Fu3 · Wei Jia4 · Yuzheng Zhuge2 · Ge Lin1

Received: 17 May 2021 / Accepted: 29 July 2021 / Published online: 14 August 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract
Pyrrolizidine alkaloids (PAs) have been found in over 6000 plants worldwide and represent the most common hepatotoxic phytotoxins. Currently, a definitive diagnostic method for PA-induced liver injury (PA-ILI) is lacking. In the present study, using a newly developed analytical method, we identified four pyrrole-amino acid adducts (PAAAs), namely pyrrole-7-cysteine, pyrrole-9-cysteine, pyrrole-9-histidine, and pyrrole-7-acetylcysteine, which are generated from reactive pyrrolic metabolites of PAs, in the urine of PA-treated male Sprague Dawley rats and PA-ILI patients. The elimination profiles, abundance, and persistence of PAAAs were systematically investigated first in PA-treated rat models via oral administration of retrorsine at a single dose of 40 mg/kg and multiple doses of 5 mg/kg/day for 14 consecutive days, confirming that these urinary excreted PAAAs were derived specifically from PA exposure. Moreover, we determined that these PAAAs were detected in ~82% (129/158) of urine samples collected from ~91% (58/64) of PA-ILI patients with pyrrole-7-cysteine and pyrrole-9-histidine detectable in urine samples collected at 3 months or longer times after hospital admission, indicating adequate persistence time for use as a clinical test. As direct evidence of PA exposure, we propose that PAAAs can be used as a biomarker of PA exposure and the measurement of urinary PAAAs could be used as a non-invasive test assisting the definitive diagnosis of PA-ILI in patients.

Keywords Hepatotoxicity · Pyrrolizidine alkaloids-induced liver injury · Pyrrole-amino acid adducts · Biomarker · Non-invasive

Introduction
Pyrrolizidine alkaloids (PAs) are a group of the most common phytotoxins that can produce toxicity in different organs, especially in the liver (He et al. 2021a; Shrenk et al. 2020; Song et al. 2020). PAs and their corresponding N-oxides are widely present in about 3% of floriferous plants globally (Mattocks 1986). More than 660 potentially poisonous PAs and PA N-oxides have been identified in over 6000 plants (Fu et al. 2004; Yang et al. 2017). Humans are readily exposed to toxic PAs through the consumption of PA-producing plants used as herbal medicines, herbal teas, and dietary supplements (Edgar et al. 2015; Kakar et al. 2010), and PA-contaminated staple foods such as grains, milk, tea, and honey (Edgar et al. 1999; He et al. 2020; Kempf et al. 2010; Zhu et al. 2018). In humans, ingestion of PAs and PA N-oxides often results in liver injury, particularly the severe PA-induced liver injury (PA-ILI) can cause hepatic
sinusoidal obstruction syndrome (HSOS) with typical symptoms of hepatomegaly, jaundice, and ascites (Chojkier 2003; DeLeve et al. 1999). However, except for the severe injury with typical HSOS syndrome and higher mortality, the relatively less severe symptoms of PA-ILI can recapitulate clinicopathological features of several kinds of acute and chronic liver diseases, such as viral hepatitis, decompensated cirrhosis, and Budd–Chiari syndrome (BCS), etc., and thus, it presents a diagnostic challenge in clinic to confirm that the liver injury is due to PA exposure.

The first human PA-poisoning cases were reported in 1920 in South Africa with 11 individuals involved and death of the majority of them (Willmot et al. 1920). Since then, over 15,000 acute PA-poisoning cases with obvious clinical symptoms have been documented worldwide in many regions/countries, including Afghanistan, China, Germany, Hong Kong, India, Jamaica, South Africa, Switzerland, the United States, etc. (Lin et al. 2011; Ma et al. 2019; Ruan et al. 2015; Zhu et al. 2020). Nevertheless, the diagnosis of the majority of these reported poisoning cases was based on typical symptoms of HSOS with either known history of exposure to PA-producing herbs or PA-contaminated food-stuffs or through retrospective investigations to confirm the PA exposure. It is very likely that much more PA-ILI cases are unaware, and currently, the risk of PA-ILI has not been addressed appropriately. Therefore, it is highly needed to develop a reliable clinical test for specific diagnosis of PA-ILI via the definitive confirmation of PA exposure.

PAs are esters comprised of a necine base and one or two ester groups connected at the C7 and C9 positions of the necine base and are classified into three types: retronecine ester groups connected at the C7 and C9 positions of the bases are highly hepatotoxic and genotoxic (Fu et al. 2004; ILI via the definitive confirmation of PA exposure. Therefore, it is highly needed to assist the definitive diagnosis of PA-ILI in the clinic.

Experimental section

Chemicals

Retrorsine (RTS) and monocrotaline were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ketamine and xylazine were obtained from Alfasan (Woerden, Holland). Four PAAA standards, namely pyrrolo-7-cysteine, pyrrolo-9-cysteine, pyrrolo-9-histidine, and pyrrolo-7-acetylcysteine, were synthesized by our group as reported previously (He et al. 2016a, 2016b; Xia et al. 2018); (e) binding with cellular DNA to form pyrrole-DNA adducts (He et al. 2021b; Xia et al. 2013; Zhu et al. 2017). The above-described pyrrolic adducts are also produced through reactions with the more long-lived hydrolysis product, DHP (Edgar et al. 2015; Fu 2017) (Fig. 1). All these pyrrolic adducts have been shown to be potentially responsible for PA-ILI and/or PA-induced liver tumor initiation. On the other hand, some of the aforementioned pyrrolic adducts undergo further degradation to generate PAAAs, which plus initially formed PAAAs via pathway (f) eventually excrete from urine (Fig. 1).

Previously, we have developed a specific pre-column derivatization method followed by ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS) analysis to measure pyrrole–plasma protein adducts in both PA-treated experimental animals and PA-exposed human samples (Lin et al. 2011; Ruan et al. 2015; The USA Centers for Disease Control and Prevention (CDC) 2012; Yang et al. 2017). We further established pyrrole–hemoglobin adducts, another type of blood PPAs with the advantage of longer persistence in PA-ILI patients for the definitive test of PA exposure (Ma et al. 2019, 2020). However, the analysis of blood PPAs has the following drawbacks: (1) an invasive (or a quasi-non-invasive) sample collection procedure, and (2) the requirement of chemical degradation of PPAs into derivatives prior to the analysis. Therefore, in the present study, we developed a UHPLC–MS/MS analytical method for directly detecting 4 PAAAs in the urine of PA-treated rats and PA-ILI patients. We propose that these urinary PAAAs can be used as a novel non-invasive biomarker for assisting the definitive diagnosis of PA-ILI in the clinic.
Fig. 1 A schematic illustration of metabolic activation of toxic PAs to the formation of pyrrole–protein adducts, pyrrole–GSH adducts, and pyrrole–amino acid adducts. The former two types of adducts are further degraded to pyrrole-amino acid adducts. Eventually all pyrrole–amino acid adducts are excreted from urine. The chemical structures of four pyrrole-amino acid adducts (PAAAs) (pyrrole-7-cysteine, pyrrole-9-cysteine, pyrrole-9-histidine, and pyrrole-7-acetylcysteine) detected in RTS-treated rat and PA-ILI patient urine samples are also illustrated. DHPAs, dehydropyrrolizidine alkaloids; DHP, (+)-6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine
Animal experiment

The care of rats and all experimental procedures were reviewed and approved by the Animal Experimental Ethics Committee of the Chinese University of Hong Kong under the regulations of the Hong Kong Special Administrative Region government. Male Sprague Dawley (SD) rats (weight 180–200 g, age 7–8 weeks) were supplied by the Laboratory Animal Service Center, the Chinese University of Hong Kong. For the single-dose study, rats (n = 5) were orally administered with a single dose of RTS (a representative toxic PA to induce PA-ILI in rat models (Lin et al. 2011; Ruan et al. 2015; Zhu et al. 2017)) at 40 mg/kg and sacrificed on 14 days after dosing. For the multiple-dose study, rats (n = 5) were orally administered 5 mg RTS/kg/day for 14 consecutive days and sacrificed 28 days after the last dosing. Upon sacrifice, liver tissues were removed for further analysis. For both studies, rats (n = 5) treated in parallel with water served as controls. All treated rats were placed individually in metabolic cages and allowed free access to water and food. The 24-h (0–24 h) urine samples of individual rats were collected daily into sterilized containers kept on ice throughout the study. Collected urine samples were stored at −80 °C until PAAA analysis. The volume of individual urine samples was measured and recorded. An aliquot (200 μL) of urine sample was filtered and centrifuged at 20,000 × g for 15 min at 4 °C. The supernatant was collected, filtered, and subjected to UHPLC–MS/MS analysis.

Hematoxylin and eosin (H&E) staining

Liver samples were fixed in 4% paraformaldehyde (PFA) for 18 h at 4 °C and embedded in paraffin blocks, which were further sectioned at 5 μm and stained with H&E. The sections were then examined for liver injury parameters such as central vein endothelial damage and sinusoidal dilation with a Q-imaging digital camera and Axiophot 2 upright microscope (Axioplan 2, Zeiss).

Immunohistochemical staining

The typical features of PA-induced HSOS were evaluated using our previously reported immunohistochemical staining method (Li et al. 2018; Yang et al. 2017). Rat liver samples were embedded in Tissue-Tek® optimum cutting temperature (O.C.T.) compound, cut into 7-μm sections, and mounted onto positively charged microslides (Super Plus slide, Menzel-Glaser). After blocking with 10% goat serum for 1 h, the liver sections were incubated with anti-endothelial cell antibody (RECA-1) (1:100 in blocking solution comprising 10% goat serum) overnight at 4 °C. Then, the liver sections were washed with PBS/0.2% Tween 20 (PBST) and incubated with goat anti-mouse IgG secondary antibody (Alexa Fluor® 488) for 1 h at room temperature. The resultant tissue slides were stained with 4′,6-diamidino-2-phenylindole (DAPI), followed by observation under a confocal system with the inverted microscope (Olympus Fluoview FV1000) with a 40× objective lens.

Urine samples from PA-ILI patients

After we successfully developed the analysis of urinary PAAAs in rat models, 64 PA-ILI patients admitted to Nanjing Drum Tower Hospital, Nanjing, China, from January to October 2019, were recruited retrospectively or at admission for the urinary PAAA study after approval by the ethics committee and acquisition of informed consent. All patients claimed consumption of herb ‘Tu-San-Qi’ (Gynura japonica) as tonics for self-medication before the onset of liver injury with similar symptoms as those of our previously reported PA-ILI patients (Gao et al. 2012, 2015; Ruan et al. 2015). Diagnosis of PA-ILI from these DILI patients included that they: (1) met the diagnostic criteria for DILI with Roussel Uclaf Causality Assessment Method (RUCAM) score > 5 (Danan et al. 2016; García-Cortés et al. 2011); (2) met the “Nanjing criteria” for PA-induced HSOS (Zhuge et al. 2019); and (3) claimed a history of the intake of ‘Tu-San-Qi’, a known PA-producing herb (Ruan et al. 2015; Yang et al. 2017), for self-health improvement; however, no ingested herbal sample was provided by these patients. A total of 158 urine samples were collected at different times from 64 PA-ILI patients for the analysis of PAAAs. Among these patients, blood specimens were also collected in 43 patients and had been tested for blood PPAs in our previously reported study (Ma et al. 2020). The detailed demographics of these 64 PA-ILI patients, number of urine samples collected in individual patients, and the indication of 43 patients with their blood PPAs tested are provided in Table S1. In addition, urine samples collected from ten healthy volunteers who did not take ‘Tu-San-Qi’ or any other PA-containing products were used as controls. All collected urine samples were stored at −80 °C until PAAA analysis. An aliquot (200 μL) of each urine sample was filtered and centrifuged at 20,000×g for 15 min at 4 °C. The supernatant was collected, filtered, and subjected to UHPLC–MS/MS analysis.

Analysis of PAAAs in urine samples by UHPLC–MS/MS

Identification and quantitation of PAAAs were performed on an Agilent 6460 Triple Quadrupole UHPLC-MS/MS System using a Waters Acquity BEH C18 column (2.1 × 100 mm, 1.7 μm). A binary LC gradient was applied to the analytical column to separate PAAAs from the urine sample. Mobile phase A was 0.1% formic acid in water and mobile phase B...
Data analysis

Urine kinetic parameters for both single-dose and multiple-dose studies in rats were obtained using WinNonlin (Pharsight Corporation, Mountain View, CA, USA, version 4.0). The elimination half-life ($t_{1/2}$) value was calculated based on the semi-logarithmic daily excretion rate ($\Delta X_u/\Delta t$) versus the mid-point of collection time interval profile. $\Delta X_u/\Delta t$ was calculated by multiplying urinary PAAA concentrations by the volume of corresponding 0–24 urine samples. Data are expressed as mean ± standard deviation (SD) for the results of method validation and demographics and mean ± standard error of mean (SEM) for all other measurements. All data analyses were performed by GraphPad Prism 6.0 (GraphPad Software Inc, San Diego, CA).

Results

Detection of PAAAs in urine

Four PAAAs, pyrrole-7-cysteine, pyrrole-9-cysteine, pyrrole-9-histidine, and pyrrole-7-acetylcysteine, were identified and quantified in the urine of RTS-treated rats and PA-ILI patients by UHPLC–MS/MS (Figure S2). The fully validated quantitative method with determined regression equations, linearity ranges, and correlation coefficients is summarized in Table S2. Correlation coefficient values ($r^2$) for the linearity of all calibration curves of 4 PAAAs were all higher than 0.993, indicating appropriate correlations within the test ranges. For all PAAAs, LOD and LOQ values were in the ranges of 0.16–0.81 nM and 0.54–2.70 nM, and overall intra- and inter-day variations (RSD%) were in the range of 1.34–3.79% and 1.94–5.36%, respectively. The matrix effect was assessed by analyzing PAAA-free urine samples from 6 untreated SD rats and 10 healthy human volunteers. Each sample was analyzed for the exclusion of any endogenous co-eluting interferences within the peak regions of the investigated PAAAs. Calibration curves were constructed by plotting the peak area versus the concentration of each PAAA standard dissolved in distilled water. The limit of detection (LOD) and limit of quantitation (LOQ) were determined at a signal-to-noise (S/N) ratio of about 3 and 10, respectively. The intra- and inter-day precisions were assessed by analyzing three concentrations of standards within 1 day or for 3 consecutive days, respectively. Precision was calculated and expressed in terms of % relative standard deviation (RSD, %). The matrix effect was evaluated at three concentrations, in triplicate, by comparing the peak area of individual PAAA standards spiked in blank urine with that spiked in distilled water in triplicate. Method stability, including freeze–thaw stability, autosampler stability at 4 °C, and long-term stability at −80 °C, was evaluated in triplicate.

PAAAs in urine of single-dose RTS-treated rats

Based on our previous studies on RTS-induced liver injury rat models (Lin et al. 2011; Ruan et al. 2015; Zhu et al. 2017), a single dose of 40 mg RTS/kg was used to induce hepatotoxicity in rats. H&E and immunohistochemical staining results showed that RTS induced apparent hepatic sinusoidal dilation and endothelial cell damage around the central veins, which are typical features of HSOS (Fig. 2A and B). Four PAAAs were detected in the urine of all RTS-treated rats (Fig. 3A) but not in the urine of control
1. Considering daily excretion, pyrrole-7-acetylcysteine was excreted in the greatest amount, and pyrrole-9-cysteine was excreted in a significantly greater amount than that of the other 2 PAAAs for all detectable days (Fig. 3A). About 90% of total pyrrole-7-cysteine and pyrrole-9-cysteine excretions occurred within 24 h, while pyrrole-9-histidine and pyrrole-7-acetylcysteine excretion showed a slower elimination with most excretion occurring within 1–4 days followed by a slower phase of final elimination (Fig. 3A). Except for pyrrole-7-cysteine, which was

### A Single-dose treatment

| Control | RTS |
|---------|-----|
| PT      | PT  |
| CV      | CV  |

### Multiple-dose treatment

| Control | RTS |
|---------|-----|
| CV      | CV  |

**Fig. 2** Histological observation of rat liver injury. A Representative H&E-stained liver sections show sinusoidal dilation (○) in RTS-treated rats (200× magnification; scale bar 100 μm). PT designates portal vein. CV designates central vein. B The representative immunohistochemical staining on sinusoidal endothelial cells using RECA-1 in green and nuclei using DAPI in blue of rat liver Sects. (400× magnification; scale bar 50 μm). Indicates that endothelial cells are partly detached from lumen surface of CV. * indicates that injured sinusoids have a larger space with wider gaps among individual sinusoids.

### A Single-dose treatment

**Fig. 3** Urinary excretion amount-time profiles of pyrrole-7-cysteine, pyrrole-9-cysteine, pyrrole-9-histidine and pyrrole-7-acetylcysteine of A rats (n = 5) orally administered with 40 mg/kg of RTS and B rats (n = 5) orally administered with 5 mg/kg/day of RTS for 14 consecutive days. The semi-logarithmic daily excretion rate (∆Xu/∆t) versus the mid-point of collection time interval profiles for individual PAAAs.
only detected within 2 days after dosing, the persistence of the other 3 PAAAs was much longer and was estimated to be about 4, 6, and 50 days for pyrrole-9-cysteine, pyrrole-9-histidine and pyrrole-7-acetylcysteine, respectively (Table 1). The above results demonstrated that these 4 urinary PAAAs could be unambiguously identified in the single-dose rat model with obvious PA-induced hepatotoxicity.

**PAAAs in urine of multiple-dose RTS-treated rats**

For the multiple-dose study, 5 mg RTS/kg/day for 14 consecutive days was used to establish the rat model with low dose but prolonged exposure to PA, which is common in human PA-poisoning cases especially induced by PA-contaminated foodstuffs. All the treated rats were sacrificed at 28 days after the last dosing. Throughout the entire study, no animal death or any obvious adverse effects, such as significant body weight loss, were observed in the rats, indicating that no obvious severe toxicity occurred. H&E and immunohistochemical staining results did not show apparent hepatic morphological changes and sinusoidal damage (Fig. 2A and B), indicating that a 14-day low dose of RTS exposure did not yet induce obvious liver injury. The 4 PAAAs which were found in the single-dose RTS-treated rats were also detected in the urine samples of all multiple-dose RTS-treated rats but not in control rat urine. During the 14-day treatment period, the daily excretion of all PAAAs fluctuated within different ranges over the time (Fig. 3B). Similar to the single-dose treated rats, the daily excreted amount of pyrrole-7-acetylcysteine was the greatest with at least 100 times more than that of the other 3 PAAAs, and the amount of pyrrole-9-cysteine was significantly higher than that of pyrrole-7-cysteine and pyrrole-9-histidine in all days of the treatment period. After the withdrawal of RTS, pyrrole-7-cysteine and pyrrole-9-cysteine could not be detected on day 2 and day 5 after the last dosing, respectively, while prolonged urinary excretion of pyrrole-9-histidine and pyrrole-7-acetylcysteine were observed (Fig. 3B). The estimated persistence of pyrrole-7-acetylcysteine, pyrrole-9-histidine, and pyrrole-9-cysteine were similar to those determined in the single-dose model (Table 1). While, for pyrrole-7-acetylcysteine, after the last RTS exposure, the elimination kinetic showed nearly half of the total amount was rapidly excreted within 2 days; the remainder was then eliminated at a significantly slower rate and was still detectable on the last experimental day, i.e. 28 days after RTS withdrawal (Fig. 3B) with an estimated persistent time of 60 days (Table 1). The results demonstrated that these 4 PAAAs could also be detected in the low but prolonged PA exposure rat model with no obvious hepatotoxicity.

Based on the findings from both single- and multiple-dose rat models, the superiority of 4 PAAAs was ranked as: pyrrole-7-acetylcysteine > > > pyrrole-9-histidine ≈ pyrrole-9 cysteine > > > pyrrole-7-cysteine. Furthermore, the results indicated that daily amounts of urinary excretion of these urinary PAAAs varied significantly along with sampling time within the same animal and were not clearly related to the severity of PA-ILI. Therefore, the determination of these urinary PAAAs could serve as a specific and reliable test for PA exposure regardless of the exposed dosage regimen and the severity of the injury.

**Table 1** Kinetic parameters of urinary PAAAs in RTS-treated rats

| PAAA                  | Single dose (RTS, p.o., 40 mg/kg) | Multiple dose (RTS, p.o., 5 mg/kg/day for 14 consecutive days) |
|-----------------------|-----------------------------------|----------------------------------------------------------------|
|                       | t_{1/2}^a (day) Persistent time (day) Total excretion (nmol) (%) dosed PA | t_{1/2}^a (day) Persistent time (day) Total excretion (nmol) (%) dosed PA |
|                       | Observed Calculated^b             | Observed Calculated^b                                         |
| Pyrrole-7-cysteine    | N.A 2 N.A 8.87 ± 1.67 (0.04%)     | N.A 1 N.A 15.29 ± 2.79 (0.04%)                                |
| Pyrrole-9-cysteine    | 0.76 ± 0.05 7 8 78.53 ± 10.55 (0.34%) | 0.68 ± 0.03 4 3.4 195.34 ± 16.52 (0.49%)                     |
| Pyrrole-9-histidine   | 1.19 ± 0.07 8 6.0 11.26 ± 2.08 (0.05%) | 1.99 ± 0.16 9 10.0 10.56 ± 1.63 (0.03%)                      |
| Pyrrole-7-acetylcysteine | 10.10 ± 0.43 14^c 50.5 2594.73 ± 408.03 (11.38%) | 12.12 ± 1.39 28^c 60.6 6761.87 ± 572.90 (16.99%)            |

^aThe elimination half-life (t_{1/2}) was calculated based on the terminal phase of post-dosing period

^bThe calculated persistent time (the time after the last dosing) was estimated as five times of t_{1/2}

^cPyrrole-7-acetylcysteine was still detectable on the sacrificed day (at 14 and 28 days after withdrawal of RTS in both single- and multiple-dose studies)

N.A.: not applicable
Determination of PAAAs in urine of PA-ILI patients

Urine samples were tested from 64 PA-ILI patients (39 males and 25 females) with the median age of 65 years old ranging from 43 to 80. Demographic and clinical features of these patients are shown in (Fig. 4A). The patients all claimed the consumption of a PA-containing herb *G. japonica*, with decoction as the most common form. The onset of liver injury mainly occurred after the intake of *G. japonica* from 3 days to 5 years. Their RUCAM scores were 6.7% at 5, 60.0% at 6–8, and 33.3% at 9–10, indicating a high possibility of DILI. About 50% of patients presented as cholestatic injury, ~26% as hepatocellular injury and ~23% as mixed injury. Only a part of patients manifested typical symptoms of PA-induced HSOS, such as ascites (61/64), jaundice (36/64), and hepatomegaly (31/64), presenting a diagnostic challenge to the clinicians. Besides, most patients showed no or mildly elevated levels of conventional serological markers (ALT, AST, and total bilirubin) in routine liver function tests, further increasing the difficulties for clinical diagnosis and identification of the etiology. Furthermore, computed tomography (CT) scans were performed in limited numbers of patients, and the representative CT scan images of two patients indicated apparent pathological changes, such as hepatomegaly, patchy enhancement in the liver, and ascites, etc. (Fig. 4B, C), but cannot clearly differentiate damage severities among the patients or distinguish from other types of liver diseases.

A total of 158 urine specimens were collected from 64 PA-ILI patients at different times (Table S1). Among them, 53 patients provided urine samples upon their admission to the hospital, while 11 patients were retrospectively recruited after discharge from hospital and could not provide urine samples upon admission. Among these 11 patients, 6 patients provided only one urine sample at 6 (n=4) or 10 (n=2) months after admission. Due to the manner of recruiting patients into the study, the sampling time and number of urine samples collected from individual patients could not be as well-controlled as in a conventional well-designed cohort study. The numbers of samples from each patient collected over scattered sampling times were: 1 sample (21 patients), 2 samples (15 patients), 3 samples (12 patients), 4 samples (10 patients), 5 samples (5 patients), and 6 samples (1 patient). Detailed information on the number of urine samples from individual patients is provided in Table S1.

About 82% samples collected from ~91% of the patients showed at least one detectable PAAA (Fig. 5), while no PAAAs were detected in urine from any healthy subject. For

---

**Fig. 4** Demographic and clinical features of 64 PA-ILI patients (A). Representative CT scan imaging of patient 51 (B) shows (a) hepatomegaly, mottle-like heterogeneous enhancement in the arterial phase, thickening of hepatic artery branches, and ascites; (b) heterogeneous, patchy decreased density of the hepatic parenchyma and ascites. Representative CT scan imaging of patient 53 (C) shows (a) hepatomegaly, diffuse patchy hepatic enhancement; (b) heterogeneous, patchy decreased density of the hepatic parenchyma and ascites. RUCAM, Roussel Uclaf Causality Assessment Method; ALT normal reference range: <40 U/L; AST normal reference range: <35 U/L; total bilirubin normal reference range: 5–28 µmol/L (Zhu et al. 2020)
the quantitation, different from the animal study, PAAA urinary concentrations rather than total daily excreted amounts were measured, because small volumes of urine sample rather than a total 24-h urine sample were collected. The number of PAAAs and their urinary concentrations in individual patients varied significantly, while in general urinary levels of all 4 PAAAs gradually decreased with time (Fig. 5). Due to the nature of this non-cohort toxicological study with scattered sampling times from individual patients, we selected ten urine samples collected at 3 months after hospital admission, which could be considered as the longest sampling time with adequate samples, to further estimate the persistence of individual PAAAs. Results indicated that pyrrole-7-cysteine (Fig. 5A) and pyrrole-9-histidine (Fig. 5C) were detected in 40% and 10% of all 3-month urine samples, while both pyrrole-9-cysteine (Fig. 5B) and pyrrole-7-acetylcysteine (Fig. 5D) were not detected in any 3-month urine samples. In addition, pyrrole-7-cysteine was detected in 1/4 of 6-month and 1/2 of 10-month urine samples (Fig. 5A), while pyrrole-9-histidine was detected in 1/2 of 5-month urine samples (Fig. 5C), indicating both pyrrole-7-cysteine and pyrrole-9-histidine showed significantly longer persistence. However, the numbers (n = 8) of samples collected at 5 months or beyond were limited and were the only sample provided by each of eight patients who were admitted to and discharged from the hospital prior to the start of the present study. These patients were recruited and sampled only when they re-visited the hospital after discharge. Further tests of more samples repeatedly collected from individual patients over comparable periods are warranted to confirm such long persistence of these two PAAAs.

Furthermore, about 2–5 urine samples were repeatedly collected upon admission until 1 month after admission in ten patients. Similar to the results of rat studies, both presence and concentration of urinary 4 PAAAs varied remarkably at different times. For instances, in the samples...
collected upon or 1 month after admission, the PAAA-positive rate was 20% or 10% for all 4 PAAAs; 40% or 10% for 3 PAAAs; 10% or 60% for 2 PAAAs, and 20% or 10% for 1 PAAA (Fig. 6A). With the sample availability, 4 of these patients were selected for further investigation of urinary PAAA excretion kinetic profiles in 4–5 urine samples. In general, less numbers of PAAAs were detected along with time and urinary concentrations of pyrrole-7-acetylcysteine were significantly lower than that of other 3 PAAAs at all sampling times in all four patients (Fig. 6B). For individual PAAAs, scattered urine concentrations were observed along with time, which were mainly affected by the varied volume and frequency of bladder emptying, and different excretion kinetics of individual PAAAs.

Considering all results, especially the maximum and median concentrations determined in urine collected within 3 months after admission (Table 2), the order for the determination of 4 PAAAs in humans appeared to be pyrrole-7-cysteine > pyrrole-9-histidine ≈ pyrrole-9-cysteine > pyrrole-7-acetylcysteine. Apparently, the detection rank order of 4 PAAAs was different in human and rats and the reasons for such difference are explained in the following discussion session. Nevertheless, based on the findings in human, we suggested that the combined application of all 4 PAAAs with the detection of at least one of them could be regarded as PAAA-positive, and such combined PAAA application could remarkably improve positive detection (Fig. 5E).

In addition, the clinic features of the aforementioned 4 representative patients were also compared and found without specific differences in symptoms of liver injury with no or mildly elevated ALT, AST, and total bilirubin levels measured upon admission (Table 3). Although the results of liver CT scans or histological examination indicated apparent pathological changes, the severity varied among individuals and was indistinguishable from possible diagnoses from other insults, such as BCS, decompensated cirrhosis, infection, alcoholic, or other drugs. Furthermore, similar

---

**Fig. 6** The percentage of individual PAAAs detected in urine samples from ten patients collected upon hospital admission and 1 month after admission (A), and the concentration of individual PAAAs determined in urine samples from 4 patients collected at 4 (Patient 31 and Patient 41) or 5 (Patient 50 and Patient 53) different times (B).
to the results obtained from rat models, the findings also revealed no obvious correlation between urinary PAAAs levels and clinical characteristics (such as serum ALT and AST levels) measured upon admission of 53 PA-ILI patients (Figure S3). On the other hand, the findings from urinary test revealed the unequivocal presence of 4 PAAAs in urines collected at different times from all patients, which provide reliable evidence for PA exposure, and thus could be used as a specific test to diagnose PA-ILI in the clinic.

### Discussion

In the present study, we reported the development of a non-invasive approach for the identification of PA-ILI in the clinic. We first identified and quantified 4 PAAAs, pyrrole-7-acetylcysteine, pyrrole-9-histidine, pyrrole-9-cysteine, and pyrrole-7-cysteine, in the urine of rats treated with RTS in both single- and multiple-dose models. Orders for the excretion amounts of PAAAs were found similar in both models with pyrrole-7-acetylcysteine being predominant. We further confirmed that these 4 PAAAs were also excreted in the urine of PA-ILI patients with at least 1 PAAA detected in ~91% patients (Fig. 5), while no PAAAs were detected from urine of healthy people. This developed clinical approach for testing PAAAs in the urine of PA-ILI patients requires a low sample volume (200 µl urine), minimal sample handling and fast sample processing (within 30 min), and moderate instrument time (27 min in LC gradient), providing the first non-invasive diagnosis of PA exposure in patients.

Currently, the causes of formation for these PAAAs are largely unclear. To date, only pyrrole-7-acetylcysteine has been detected in the urine of male SD rats administered 14C-monocrotaline or 14C-senecionine (Estep et al. 1990). Moreover, pyrrole-7-cysteine was identified from human and rat liver microsomal metabolism of riddelliine via CYPs-mediated formation of DHPA followed by interaction with cysteine (He et al. 2016b). Limited available information suggests that urinary PAAAs can not only be degraded from PPAs bound with blood proteins and other proteins in various organs/tissues, but also from the direct binding of DHPAs with GSH and amino acids in the body (Fig. 1), which therefore can result in higher concentrations and longer persistence than that of PPAs in blood. The formation of xenobiotic-derived GSH adducts followed by sequential enzymes-mediated degradations to generate cysteinylglycine adducts, cysteine adducts and acetylcysteine adducts, are called mercapturic degradation pathway, which is generally considered as a detoxication pathway for xenobiotics. The resultant degraded adducts, especially cysteine adducts and acetylcysteine adducts, which are called mercapturic acids via N-acetylation of cysteine adducts, are polar and readily excreted from urine (Hanna et al. 2019). Nevertheless, the detailed mechanisms underlying the PAAAs formation via

### Table 2

| Sampling time | Pyrrole-7-cysteine | Pyrrole-9-cysteine | Pyrrole-9-histidine | Pyrrole-7-acetylcysteine |
|---------------|-------------------|-------------------|--------------------|-------------------------|
| Admission     | 8.97 (3.78–153.37)| 12.29 (1.16–35.63)| 5.70 (1.33–44.67)  | 1.55 (1.07–11.25)       |
| 1 week        | 16.78 (4.91–155.66)| 9.07 (1.29–45.54) | 15.61 (1.70–47.18) | 1.92 (1.11–4.05)        |
| 2 weeks       | 8.24 (4.07–20.94) | 10.55 (3.09–19.55)| 7.18 (1.41–26.92)  | 1.75 (1.66–2.38)        |
| 3 weeks       | 6.09 (2.83–46.55) | 6.18 (4.63–7.72)  | 6.18 (1.48–28.99)  | 3.51 (3.38–3.63)        |
| 1 month       | 5.73 (3.03–58.84) | 4.63 (2.45–5.15)  | 8.43 (1.48–21.89)  | 1.11a                   |
| 2 months      | 4.97 (4.40–5.53)  | 5.60 (2.32–8.88)  | 2.52 (1.48–2.96)   | N.D                     |
| 3 months      | 5.22 (4.29–10.24) | N.D               | 1.56a              | N.D                     |

N.D.: not detected

### Table 3

| Patient code | P31 | P41 | P50 | P53 |
|--------------|-----|-----|-----|-----|
| RUCAM score  | 9   | 7   | 8   | 9   |

**Clinical manifestation**

- Jaundice: √ √ √ ×
- Ascites: √ √ √
- Hepatomegaly: √ √ √
- ALT (U/L) (NRR: < 40 U/L): 118.8 177 120.4 198.4
- AST (U/L) (NRR: < 35 U/L): 69.9 107 89.5 259.3
- Total bilirubin (µmol/L) (NRR: 5–28 µmol/L): 22.3 26.2 64 77.5
- CT scan or liver histological examination:
  - Patchy liver enhancement: √ √ √ √
  - Hepatic vein stenosis: √ × √ ×
  - Hepatic sinusoidal dilation and degeneration: √ × × ×
  - Hemorrhage: √ × × ×

NRR: normal reference range (Zhu et al. 2020)
breakdown from different pyrrole proteins and urinary elimination are largely unknown and warrant future investigation.

In patient urine, pyrrole-7-cysteine was predominant with the longest persistence and pyrrole-7-acetylcysteine showed the lowest concentrations with the shortest persistence, while opposite observations were found in PA-treated rats. Because these 2 PAAAs are interconverted via N-acetylation and N-deacetylation in the body (Fig. 1), there are three plausible explanations for the observed species difference. First, rats have been reported to have a significantly higher S-conjugate N-acetyltransferase activity than humans (Chasseaud 1976; Green et al. 2003; Heuner et al. 1991). Second, aminoacylases, which hydrolyze acetylated cysteine S-adducts back to cysteine S-adducts via N-deacetylation, are defective in rat species (Anders et al. 1994; Hanna et al. 2019). Third, the rate of N-deacetylation was greater than that of N-acetylation in humans (Altuntas et al. 2002). Therefore, with lower N-acetylation of cysteine S-adduct but higher N-deacetylation of acetylated cysteine S-adducts, pyrrole-7-cysteine was excreted as a predominant form, while pyrrole-7-acetylcysteine was excreted as a minor form in the urine of PA-ILI patients. However, for a confirmative comparison, both sexes of different species should be involved, while only male rat was investigated in the present study; therefore, a more comprehensive investigation with both sexes of rat and human is warranted in the future study.

Apart from the significant differences in urinary excretion and persistence of pyrrole-7-cysteine and pyrrole-7-acetylcysteine between PA-ILI patients and PA-treated rats, quantitative measurements of 4 PAAAs were also different between human and rat urine samples. While daily excreted amounts of individual PAAAs were determined from the total urine excreted from rats, more practical for the clinical test, only small volume of urine was collected from patients, and thus, concentration rather than total daily amount of individual PAAAs in urine was determined. However, concentrations of individual PAAAs in the urine continuously change with time due to variations of urine volume and frequency of bladder emptying. Therefore, unavoidably, the selection of a particular PAAA as the test for PA exposure may lead to a false-negative result, while the simultaneous determination of 4 PAAAs would undoubtedly assist the confirmative identification of PA exposure. Apparently because of the aforementioned species difference, the study of kinetics of urinary elimination of PAAAs in PA-ILI patients is significantly challenging and cannot be predicted from the data determined from PA-treated rats. Nevertheless, further investigations on human urinary elimination kinetics of PAAAs are certainly warranted.

The results obtained from both PA-treated rats and PA-ILI patients demonstrated that either total amounts or concentrations of PAAAs in urine could not be directly correlated to the severity of PA-ILI. Besides, the levels of urinary PAAAs may also vary due to other factors, including (a) amount and type of PAs consumed, (b) duration of consumption, and (c) time of specimen sampling. These information are usually lacking or cannot be provided accurately in most clinical poisoning cases, because it is not a general practice to properly record such information by consumers who expose to PA-containing products for self-medication, self-health-improvement, or accidental consumption of PA-containing products and/or PA-contaminated foodstuffs. Therefore, similar to the viral RNA fragment test for the diagnosis of coronavirus disease 2019 to confirm that the subject is infected by coronavirus 2 but unrelated to the severity of the infectious, the detection of PAAAs can only provide the positive result for PA exposure, but not directly reflect the severity of liver injury.

The value of any biomonitoring approach depends upon its ability to accurately classify individuals with disparate exposures and, ultimately, the risk of disease. Therefore, the method described here was used to discriminate between individuals with disparate exposures of PAs.

Currently, there is no officially approved biomarker/test to definitively identify PA exposure as the cause of liver injury in patients. On the other hand, our previously developed blood PPA test, in particular serum/plasma pyrrole–plasma protein adducts (PPPAs) test, has been applied for clinic test to confirm PA exposure and confirmative diagnosis of PA-ILI in many liver injury patients in China (Lin et al. 2011; Ruan et al. 2015; Yang et al. 2017) and Ethiopia (The USA Centers for Disease Control and Prevention (CDC) 2012), and has also been recommended by The Hepatobiliary Diseases Committee of Chinese Society of Gastroenterology to include blood PPPA test as one of the diagnostic criteria for PA-induced HSOS, in case patients cannot provide the history or only provide an ambiguous history of the intake of drug/herb (Zhuge et al. 2019). Recently, we further developed a pyrrole–hemoglobin adducts (PHAs) test in red blood cells (Ma et al. 2019) and revealed that PHAs had significantly higher level and longer persistence than that of PPPAs (Ma et al. 2020). In the present 64 PA-ILI patients with urinary PAAAs test, 43 patients have been previously tested for both PPPAs and PHAs (Table S1) (Ma et al. 2020). Comparing the results among blood PPPA and PHA tests, and urinary PAAAs test in 43 patients, although the number of specimens collected and the sampling times for blood and urine samples were different in many patients, PAAAs-positive results were obtained in all PHAs positive patients, while about 79% (34/43) patients were PPPAs positive (Ma et al. 2020). With the limited number of samples collected at different sampling times, the persistence of urine PAAAs appeared to be longer than that of blood PHAs; however, further investigation with adequate number and time for both biological specimens are required to confirm this finding. Taken together, the urinary PAAAs test has the advantages
of a non-invasive approach, simple sample preparation process, direct analysis, and potentially longer persistence over the currently available PA exposure biomarkers, namely blood PPPAs and PHAs.

In conclusion, a novel and non-invasive test of four urinary PAAAs has been developed for a specific determination of PA exposure in PA-ILI patients. We propose PAAAs as the non-invasive biomarker of PA exposure, and the measurement of all 4 PAAAs with the consideration of at least one detectable PAAA in the urine as the unequivocal identification of PA exposure in suspected patients for assisting the definitive diagnosis of PA-ILI in the clinic.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00204-021-03129-6.

Funding The present study was supported by Research Grant Council of Hong Kong SAR (GRF Grant No. 14106318) and CUHK Direct Grant (Grant No: 4054503). This article is not an official USA Food and Drug Administration (FDA) guidance or policy statement. No official support or endorsement by the USA FDA is intended or should be inferred.

Declarations

Conflict of interest Ge Lin, Lin Zhu, Jiang Ma, Chunyuan Zhang, and Yisheng He have a patent (USA Provisional Patent No.: 62/987,769) related to this work. Other authors have declared no potential conflicts of interest.

References

Altuntas TG, Kharasch ED (2002) Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and b-lyase-catalyzed metabolism. Drug Metab Dispos 30(2):148–154

Anders MW, Dekant W (1994) Aminoacylases. Adv Pharmacol 27:433–448

Center for Drug Evaluation and Research, USA Food and Drug Administration. (2018). Bioanalytical Method Validation Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance

Cao Y, Colegate SM, Edgar JA (2008) Safety assessment of food and herbal products containing hepatotoxic pyrrolizidine alkaloids: interlaboratory consistency and the importance of N-octide determination. Phytochem Anal 19(6):526–533

Chasseaud LF (1976) Conjugation with glutathione and mercapturic acid excretion. In: Arias IM, Jakoby W (eds) Glutathione: metabolism and function. Raven Press, New York, pp 77–114

Chojkier M (2003) Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol 39(3):437–446

Danan G, Teschke R (2016) RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci 17(1):14

DeLeve LD, McCuskey RS, Wang X, Hu L, McCuskey MK, Epstein RB, Kanel GC (1999) Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 29(6):1779–1791

Edgar JA, Molyneux RJ, Colegate SM (2015) Pyrrolizidine alkaloids: potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol 28(1):4–20

Edgar JA, Smith LW. (1999). Transfer of pyrrolizidine alkaloids into eggs: food safety implications. ACS Symposium Series. Volume 745, Chapter 8:118–128.

Estep JE, Lame MW, Jones AD, Segall HJ (1990) N-acetylcyesteine-conjugatedpyrrole identified in rat urine following administration of two pyrrolizidine alkaloids, monocrotaline and seneconine. Toxicol Lett 54(1):61–69

Fu PP, Xia Q, Lin G, Chou MW (2004) Pyrrolizidine alkaloids—genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 36(1):1–55

Fu pp. (2017) Pyrrolizidine alkaloids: metabolic activation pathways leading to liver tumor initiation. Chem Res Toxicol 30(1):81–93

Gao H, Li N, Wang J, Zhang S, Lin G (2012) Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis 13(1):33–39

Gao H, Ruan J, Chen J, Li N, Ke C, Ye Y, Lin G, Wang J (2015) Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des Ther 9:4861–4868

García-Cortés M, Stephens C, Lucena MI, Fernández-Castañer A, Andrade RJ (2011) Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 55(3):683–691

Green T, Lee R, Farrar D, Hill J (2003) Assessing the health risks following environmental exposure to hexachlorobutadiene. Toxicol Lett 138(1–2):63–73

Hanna PE, Anders MW (2019) The mercapturic acid pathway. Crit Rev Toxicol 49(10):819–929

He XB, Ma L, Xia QS, Fu PP (2016a) 7-N-Acetylcyesteine-pyrrole conjugated-a potent DNA reactive metabolite of pyrrolizidine alkaloids. J Food Drug Anal 24(4):682–694

He XB, Xia QS, Ma L, Fu PP (2016b) 7-cysteine-pyrrole conjugate: A new potential DNA reactive metabolite of pyrrolizidine alkaloids. J Environ Sci Health, Part C Environ Carcinog Ecotoxicol Rev 34(1):57–76

He Y, Zhu L, Ma J, Wong L, Zhao Z, Ye Y, Fu PP, Lin G (2020) Comprehensive investigation and risk study on pyrrolizidine alkaloid contamination in Chinese retail honey. Environ Pollut 267:115542. https://doi.org/10.1016/j.envpol.2020.115542

He Y, Lian W, Ding L, Fan X, Ma J, Zhang QY, Ding X, Lin G (2021a) Lung injury induced by pyrrolizidine alkaloids depends on metabolism by hepatic cytochrome P450s and blood transport of reactive metabolites. Arch Toxicol 95(1):103–116

He Y, Shi M, Wu X, Ma J, Ng TP, Xia Q, Zhu L, Fu PP, Man K, Tsui KW, Lin G (2021b) Mutational signature analysis reveals widespread contribution of pyrrolizidine alkaloid exposure to human liver cancer. Hepatology. https://doi.org/10.1002/hep.31723

Heuner A, Dekant W, Schweger JS, Silbernagl S (1991) Localization and capacity of the last step of mercapturic acid biosynthesis and the reabsorption and acetylation of cysteine S-conjugates in the rat kidney. Pflügers Archiv European J Physiol 417(5):523–527

Kakar F, Akbarian Z, Leslie T, Mustafa ML, Watson J, van Egmond HP, Omar MF, Mofleh J (2010) An outbreak of hepatic veno-occlusive disease in Western Afghanistan associated with exposure to wheat flour contaminated with pyrrolizidine alkaloids. J Toxicol 2010:7. https://doi.org/10.1155/2010/313280

Kempf M, Heil S, Haßlauer I, Schmidt L, von der Ohe K, Theuring C, HP, Omar MP, Mofleh J (2010) An outbreak of hepatic veno-occlusive disease in Western Afghanistan associated with exposure to wheat flour contaminated with pyrrolizidine alkaloids. J Toxicol 2010:7. https://doi.org/10.1155/2010/313280

Li YH, Tai WCS, Khan I, Lu C, Lu Y, Wong WY, Chan WY, Hsiao WLW, Lin G (2018) Toxicoproteomic assessment of liver responses to acute pyrrolizidine alkaloid intoxication in rats. J
Environ Sci Health, Part C Environ Carcinog Ecotoxicol Rev 36(2):65–83

Lin G, Cui YY, Hawes EM (2000) Characterization of rat liver microsomal metabolites of clivorne, an hepatotoxic otonecine-type pyrrolizidine alkaloid. Drug Metab Dispos 28(12):1475–1483

Lin G, Wang JY, Li N, Li M, Gao H, Ji Y, Zhang F, Wang H, Zhou Y, Ye Y, Xu HX, Zheng J (2011) Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol 54(4):666–673

Lu Y, Ma J, Song Z, Ye Y, Fu PP, Lin G (2018) The role of formation of pyrrole-ATP synthase subunit beta adduct in pyrrolizidine alkaloid-induced hepatotoxicity. Arch Toxicol 92(11):3403–3414

Ma L, Zhao HQ, Xia Q, Cai L, Fu pp. (2015) Synthesis and phototoxicity of isomeric 7,9-diglutathione pyrrole adducts: Formation of reactive oxygen species and induction of lipid peroxidation. J Food Drug Anal 23(3):577–586

Ma J, Ruan JQ, Chen XM, Li DP, Yao S, Fu PP, Ye Y, Gao H, Wang JY, Lin G (2019) Pyrrole-hemoglobin adducts, a more feasible potential biomarker of pyrrolizidine alkaloid exposure. Chem Res Toxicol 32:1027–1039

Ma J, Zhang H, He YS et al (2020) Clinical application of pyrrole-hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans. Arch Toxicol. https://doi.org/10.1007/s00204-020-02947-4

Mattocks AR (1982) Hydrolysis and hepatotoxicity of retronecine diesters. Toxicology Letter 14(1-2):111–116

Mattocks AR (1986) Chemistry and toxicology of pyrrolizidine alkaloids. Academic Press, London

Molyneux R, Gardner D, Colegate S, Edgar J (2011) Pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome in humans. Lancet 196(5069):848–849

Xia Q, Zhao Y, von Tungeln LS, Doerge DR, Lin G, Cai L, Fu PP (2013) Pyrrolizidine alkaloid-derived DNA adducts as a common biological biomarker of pyrrolizidine alkaloid-induced tumorigenicity. Chem Res Toxicol 26(9):1384–1396

Xia Q, He X, Ma L, Chen SJ, Fu pp. (2018) Pyrrolizidine alkaloid secondary pyrrole metabolites construct multiple activation pathways leading to DNA adduct formation and potential liver tumor initiation. Chem Res Toxicol 31(7):619–628

Yang MB, Ruan JQ, Gao H, Li N, Ma J, Xue JY, Ye Y, Fu PP, Wang JY, Lin G (2017) First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans. Arch Toxicol 91(12):3913–3925

Yang MB, Ma J, Ruan JQ, Ye Y, Fu PP, Lin G (2019) Intestinal and hepatic biotransformation of pyrrolizidine alkaloid N-oxides to toxic pyrrolizidine alkaloids. Arch Toxicol 93(8):2197–2209

Zhao Y, Xia QS, Yin JJ, Lin G, Fu pp. (2011) Photodestruction of dehydropyrrolizidine alkaloids–formation of reactive oxygen species and induction of lipid peroxidation. Toxicol Lett 205(3):302–309

Zhao Y, Xia Q, Gamboa da Costa G, Yu H, Cai L, Fu pp. (2012) Full structure assignments of pyrrolizidine alkaloid DNA adducts and mechanism of tumor initiation. Chem Res Toxicol 25(9):1985–1996

Zhu L, Xue J, Xia Q, Fu PP, Lin G (2017) The long persistence of pyrrolizidine alkaloid-derived DNA adducts in vivo: kinetic study following single and multiple exposures in male ICR mice. Arch Toxicol 91(2):949–965

Zhu L, Wang Z, Wong L, He Y, Zhao Z, Ye Y, Fu PP, Lin G (2018) Contamination of hepatotoxic pyrrolizidine alkaloids in retail honey in China. Food Control 85:484–494

Zhu L, Zhang CY, Li DP, Chen HB, Ma J, Gao H, Ye Y, Wang JY, Fu PP, Lin G (2020) Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China. Acta Pharamocol Sin. https://doi.org/10.1038/s41401-020-00553-9

Zhuge YZ, Liu YL, Xie WF, Zou XP, Xu JM, Wang JY, Chinese Society of Gastroenterology Committee of Hepatobiary Disease (2019) Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol 34(4):634–642

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.